학술논문
The tyrosine kinase inhibitor Dasatinibblocks in-vitro HIV-1 production by primary CD4T cells from HIV-1 infected patients
Document Type
Article
Author
Source
AIDS; January 2014, Vol. 28 Issue: 2 p278-281, 4p
Subject
Language
ISSN
02699370; 14735571
Abstract
HIV reservoirs persistence despite antiretroviral therapy (ART) might be related to persistent immune activation and residual HIV production, requiring further therapeutic strategies. We demonstrated that the tyrosine kinase inhibitor (TKI) Dasatinib, used for chronic myeloid leukaemia, significantly blocks in vitroHIV1 production by 3.4 logs in HIV1-infected primary CD4T lymphocytes, by inhibiting cell activation and proliferation, without cell toxicity. This molecule deserves to be investigated further for HIV cure strategies to hinder persistent immune activation and residual viral production.